(UroToday.com) The International Kidney Cancer Symposium 2021 annual hybrid meeting included a non-clear cell renal cell carcinoma (RCC) session and a presentation by Dr. Bradley McGregor discussing recent and future studies of systemic therapy for non-clear cell RCC. Dr. McGregor started by highlighting that non-clear cell RCC has worse outcomes than clear cell RCC. In a retrospective analysis of 4,528 patients treated with VEGF/mTOR inhibitors (n = 4,235 clear cell RCC; n = 337 non-clear cell RCC) in Pfizer sponsored phase II and III trials, non-clear cell RCC patients had worse PFS (6.1 vs 8.5 months) and OS (15.7 vs 20.2 months):1